Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Accumulated Expenses (2016 - 2026)

Corcept Therapeutics (CORT) has disclosed Accumulated Expenses for 15 consecutive years, with $80.2 million as the latest value for Q1 2026.

  • For Q1 2026, Accumulated Expenses fell 9.8% year-over-year to $80.2 million; the TTM value through Mar 2026 reached $80.2 million, down 9.8%, while the annual FY2025 figure was $90.6 million, 0.11% changed from the prior year.
  • Accumulated Expenses hit $80.2 million in Q1 2026 for Corcept Therapeutics, down from $90.6 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $108.4 million in Q3 2025 and bottomed at $13.1 million in Q1 2022.
  • Average Accumulated Expenses over 5 years is $51.8 million, with a median of $40.5 million recorded in 2022.
  • Year-over-year, Accumulated Expenses plummeted 52.4% in 2023 and then skyrocketed 467.6% in 2024.
  • Corcept Therapeutics' Accumulated Expenses stood at $14.0 million in 2022, then soared by 268.77% to $51.6 million in 2023, then surged by 75.68% to $90.7 million in 2024, then decreased by 0.11% to $90.6 million in 2025, then decreased by 11.53% to $80.2 million in 2026.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $80.2 million, $90.6 million, and $108.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.